Loading…
German maker of glass and polymer packaging such as vials, syringes and cartridges used to package injectable drugs.
German maker of glass and polymer packaging such as vials, syringes and cartridges used to package injectable drugs.
Sells vials, syringes and cartridges to drug makers in high volumes under supply agreements, as part of the approved drug's registered packaging, so changing supplier means re-approval and customers rarely switch. It is the pharmaceutical packaging arm of the SCHOTT glass group, which keeps the majority and listed it in 2023.
In one line: A German West Pharmaceutical Services/Gerresheimer peer.
Moat: narrow (regulatory licence, customer qualification, process know-how). Pharma-grade glass/polymer manufacturing with long customer qualification cycles, benefiting from GLP-1/biologics packaging demand.
Headquarters: Mainz, Germany · Founded: 2020 · Employees: 4,811
Size SCHOTT Pharma AG & Co. KGaA (1SXP.DE) is a Germany Health Care company (Medical Specialties) with a market value of $3.67B, the 85th largest of 205 Germany companies the cockpit tracks. Shares closed at €21.75 on 6 Nov 2026.
Performance Over six months the shares gained 31.3%, against +3.3% for the median peer and +2.6% for the Germany market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 4.3% over the last twelve months (peer median +3.4%); the operating margin is 15.5% (peer median 11.0%).
Valuation It trades at 22.1× forward earnings against a peer median of 20.4× (8th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 12% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.1 points above its cost of capital (7.2% WACC).
Next results Next results expected around 10 Dec 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €1.02B | €986M | €957M | €899M | €821M |
| Revenue growth | — | +3% | +7% | +9% | — |
| Gross profit | €317M | €332M | €323M | €315M | €295M |
| EBITDA | €245M | €255M | €238M | €211M | €217M |
| Net income | €137M | €146M | €150M | €152M | €125M |
| Free cash flow | €55.3M | €35.6M | €79.7M | €6.18M | €30.1M |
| Capital expenditure | €138M | €145M | €145M | €176M | €153M |
| Total debt | €0 | €83.0M | €85.8M | €72.3M | €74.8M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| SCHOTT Pharma AG & Co. KGaA 1SXP.DE | $3.67B | +31% | +4% | 15% | 22.1× | 11.7% |
| Gerresheimer GXI.DE | $1.21B | +24% | +9% | -4% | 18.0× | 55.8% |
| West Pharmaceutical Services WST | $27.9B | +23% | +13% | 23% | 39.8× | 25.2% |
| Corning GLW | $91.4B | -43% | +19% | 17% | 25.4× | 24.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1SXP.DE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -11.8% | +9.0% | 4th lowest of 21 |
| 6-month return | +31.3% | +3.3% | 7th highest of 21 |
| Distance from 52-week high | -17.0% | -26.9% | 8th highest of 21 |
| Revenue growth (TTM) | +4.3% | +3.4% | 9th highest of 19 |
| Operating margin | 15.5% | 11.0% | 4th highest of 19 |
| Forward P/E | 22.1× | 20.4× | 8th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 11.7% | 8.2% | 7th most demanding of 17 |
| Growth delivered (Del g) | +11.0% | +7.6% | 5th highest of 17 |
| Hurdle (Req g minus delivered) | +0.7 pp | +0.6 pp | 9th least demanding of 17 |
| ROIC minus cost of capital | +4.1 pp | -1.2 pp | 4th highest of 18 |
| EV / EBITDA | 13.3× | 11.1× | 4th most expensive of 10 |
| Net debt / EBITDA | -0.1× | 1.1× | 5th least indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| SCHOTT Pharma AG & Co. KGaA 1SXP.DE | Germany | $3.67B | +31% | +4% | 15% | 22.1× | 11.7% | +11.0% |
| Stevanato STVN | United States | $3.70B | -26% | +12% | 18% | 19.3× | 10.6% | +12.1% |
| Shandong Weigao Blood Purification Products 603014.SS | China | $3.63B | -3% | +4% | n/a | 20.4× | -1.2% | +8.1% |
| Andon Health 002432.SZ | China | $3.60B | -29% | -30% | -26% | 15.0× | -7.7% | -7.4% |
| iRay Technology 688301.SS | China | $3.54B | -8% | +58% | 24% | 27.5× | n/a | n/a |
| Carl Zeiss Meditec AFX.DE | Germany | $3.51B | +40% | 0% | 8% | 26.8× | 13.7% | +10.8% |
| Pulse Biosciences PLSE | United States | $3.87B | +179% | n/a | -7,008% | n/a | n/a | n/a |
| Ambu A/S AMBU-B.CO | Denmark | $3.42B | +40% | +5% | 11% | 28.1× | 12.6% | +11.1% |
| Lepu Medical Technology (Beijing) 300003.SZ | China | $3.42B | -12% | -1% | 13% | 26.3× | 9.6% | -4.2% |
| MGI Tech 688114.SS | China | $3.42B | +9% | +2% | -7% | n/a | 46.5% | -0.1% |
| Autobio Diagnostics 603658.SS | China | $3.41B | +19% | +3% | 25% | 20.6× | -0.3% | +7.2% |
| Ottobock SE & Co. KGaA OBCK.DE | Germany | $3.36B | -25% | +5% | 15% | 15.4× | 3.5% | +8.0% |
| Envista NVST | United States | $4.04B | +4% | +12% | 11% | 15.6× | 6.8% | +7.1% |
| Tecan TECN.SW | Switzerland | $4.05B | +91% | -4% | 1% | 40.1× | 46.9% | +3.8% |
| Zhende Medical 603301.SS | China | $3.33B | -8% | +8% | 7% | 43.5× | 23.2% | -16.1% |
| Sumitomo Bakelite 4203.T | Japan | $3.31B | +15% | +15% | 13% | 14.9× | 6.8% | +8.9% |
| Fielmann FIE.DE | Germany | $4.12B | +3% | +3% | 14% | 17.8× | -5.3% | +11.3% |
| CareDx CDNA | United States | $4.13B | +260% | +39% | 1% | 53.2× | n/a | n/a |
| Celcuity CELC | United States | $3.27B | -49% | n/a | n/a | n/a | n/a | n/a |
| Jiangsu Yuyue Medical Equipment & Supply 002223.SZ | China | $4.26B | -1% | -1% | 13% | 20.4× | 5.1% | +3.4% |
| Integer ITGR | United States | $4.30B | +44% | 0% | 9% | 18.8× | 19.6% | +11.5% |